| Dr Douglas Carl Melzer, MD | |
|
500 W Broadway St, Missoula, MT 59802-4008 | |
| (303) 720-9622 | |
| Not Available |
| Full Name | Dr Douglas Carl Melzer |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 14 Years |
| Location | 500 W Broadway St, Missoula, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164741864 | NPI | - | NPPES |
| 023862 | Other | CO | KAISER COMMERCIAL NUMBER |
| 69354057 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 52846 (Colorado) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Patrick Hospital | Missoula, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Mt | 6608786306 | 272 |
News Archive
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
A plan to ensure that evidence-based psychosocial interventions are routinely used in clinical practice and made a part of clinical training for mental health professionals was released today by the National Academy of Medicine.
A team of scientists led by Howard Hughes Medical Institute (HHMI) investigator Linda B. Buck has found that a drug used to treat depression can extend the lifespan of adult roundworms.
Northwest Biotherapeutics, Inc., developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.
› Verified 5 days ago
| Entity Name | Providence Health & Services Mt |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144319138 PECOS PAC ID: 6608786306 Enrollment ID: O20031229000787 |
News Archive
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
A plan to ensure that evidence-based psychosocial interventions are routinely used in clinical practice and made a part of clinical training for mental health professionals was released today by the National Academy of Medicine.
A team of scientists led by Howard Hughes Medical Institute (HHMI) investigator Linda B. Buck has found that a drug used to treat depression can extend the lifespan of adult roundworms.
Northwest Biotherapeutics, Inc., developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas Carl Melzer, MD 500 W Broadway St, Missoula, MT 59802-4008 Ph: (303) 720-9622 | Dr Douglas Carl Melzer, MD 500 W Broadway St, Missoula, MT 59802-4008 Ph: (303) 720-9622 |
News Archive
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
A plan to ensure that evidence-based psychosocial interventions are routinely used in clinical practice and made a part of clinical training for mental health professionals was released today by the National Academy of Medicine.
A team of scientists led by Howard Hughes Medical Institute (HHMI) investigator Linda B. Buck has found that a drug used to treat depression can extend the lifespan of adult roundworms.
Northwest Biotherapeutics, Inc., developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.
› Verified 5 days ago
Diana Griffith, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-728-4100 | |
Dr. Amanda A Morey, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-329-5635 | |
Dr. Kevin Granger Eichhorn, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Saint Patrick Hospital Emergency Department, 500 West Broadway, Missoula, MT 59801 Phone: 406-329-5635 | |
Elizabeth J Grimley, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 | |
David Westphal, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-721-4800 | |
Dr. Robert C Mcdevitt, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 |